All In Biotech

NDA 020726 · Novartis Pharms

Femara

Letrozole · Oral · Aromatase Inhibitor

NovelAccelerated approval

Last checked: Nov 20, 2026Latest source record: Dec 16, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1997

Jul 25, 1997

Approved uses

9

Original approval plus efficacy supplements

Registered trials

818

198 Phase 3, 130 recruiting

FAERS reports

62,445

50,509 serious, 6,134 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jun 11, 2026.

Femara is an aromatase inhibitor indicated for: Adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer. ( 1.1 ) Extended adjuvant treatment of postmenopausal women with early breast cancer who have received prior standard adjuvant tamoxifen therapy. ( 1.2 ) First and second-line treatment of postmenopausal women with hormone receptor positive or unknown advanced breast cancer. ( 1.3 ) 1.1 Adjuvant Treatment of Early Breast Cancer Femara (letrozole) is indicated for the adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer. 1.2 Extended Adjuvant Treatment of Early Breast Cancer Femara is indicated for the extended adjuvant treatment of early breast cancer in postmenopausal women, who have received 5 years of adjuvant tamoxifen therapy. The effectiveness of Femara in extended adjuvant treatment of early breast cancer is based on an analysis of disease-free survival (DFS) in patients treated with Femara for a median of 60 months [see Clinical Studies (14.2, 14.3)] . 1.3 First and Second-Line Treatment of Advanced Breast Cancer Femara is indicated for first-line treatment of postmenopausal women with hormone receptor positive or unknown, locally advanced or metastatic breast cancer. Femara is also indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following antiestrogen therapy [see Clinical Studies (14.4, 14.5)].

Mechanism: The growth of some cancers of the breast is stimulated or maintained by estrogens. Treatment of breast cancer thought to be hormonally responsive (i.e., estrogen and/or progesterone receptor positive or receptor unknown) has included a variety of efforts to decrease estrogen levels (ovariectomy, adrenalectomy, hypophysectomy) or inhibit estrogen effects (antiestrogens and progestational agents). These interventions lead to decreased tumor mass or delayed progression of tumor growth in some women. In postmenopausal women, estrogens are mainly derived from the action of the aromatase enzyme,...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Apr 30, 2010 Supplement 20 · Efficacy LetterLabel
  • Mar 2, 2010 Supplement 16 · Efficacy LabelLetter
  • Mar 2, 2010 Supplement 15 · Efficacy LabelLetter
  • Dec 28, 2005 Supplement 12 · Efficacy · priority review LabelLetter
  • Oct 29, 2004 Supplement 11 · Efficacy LabelLetter
  • Feb 26, 2003 Supplement 5 · Efficacy LabelLetter
  • Jan 17, 2003 Supplement 8 · Efficacy LetterLabel
  • Jan 10, 2001 Supplement 6 · Efficacy · priority review LabelReviewLetter
  • Jul 25, 1997 Original approval · Type 1 - New Molecular Entity Review
1 products under this application
  • FEMARA · LETROZOLE 2.5MG · TABLET, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Letrozole" as an intervention, any sponsor and status, largest first.

All 818 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • fatigue7,561
  • nausea5,594
  • neutropenia5,295
  • diarrhoea4,792
  • malignant neoplasm progression4,614
  • arthralgia4,046
  • white blood cell count decreased3,845
  • alopecia3,711
  • pain3,097
  • asthenia3,034
  • dyspnoea2,976
  • vomiting2,820

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004155
2005305
2006463
2007438
2008515
2009606
2010934
20111,099
20121,083
2013869
2014827
20151,937
20163,080
20173,344
20184,475
20195,738
20205,880
20216,044
20225,875
20235,949
20245,025
20254,538
20263,266

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Femara (Letrozole)

2024 spending

$1.3M

Beneficiaries

208

905 claims

Per beneficiary

$6,302

$25.03 per unit

View as table
YearSpending
2020$2,352,001
2021$1,950,059
2022$1,556,773
2023$1,465,126
2024$1,310,720

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 958 on PubMed

Sponsor: Novartis

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.